Targeting the renin-angiotensin-aldosterone system in atrial fibrillation: From pathophysiology to clinical trials

Journal of Human Hypertension

Volumn 19, Issue 11, 2005, Pages 855-859

  Boos, Christopher J ^a   Lip, G Y H ^a  

^a CITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; SYNAPTOPHYSIN;

CLINICAL STUDY; CLINICAL TRIAL; COMORBIDITY; DIABETES MELLITUS; DRUG MECHANISM; ENDOCRINE FUNCTION; GENE TARGETING; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEMODYNAMICS; HUMAN; HYPERTENSION; INFLAMMATION; MORBIDITY; MORTALITY; NOTE; PATHOPHYSIOLOGY; PREVALENCE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; STROKE; VASCULAR DISEASE;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; ATRIAL FIBRILLATION; HUMANS; HYPERTENSION; RECEPTOR, ANGIOTENSIN, TYPE 2; RENIN-ANGIOTENSIN SYSTEM;

EID: 27844468153     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/sj.jhh.1001933     Document Type: Note

References (49)

1. Freestone B, Lip GYH. Epidemiology and costs of cardiac arrhythmias. In: Lip GYH, Godtfredsen J (eds). Cardiac Arrhythmias: A Clinical Approach. Mosby: Edinburgh, 2003, pp 3-24.
2. Lip GY, Felmeden DC, Li-Saw-Hee FL, Beevers DG. Hypertensive heart disease. A complex syndrome or a hypertensive 'cardiomyopathy'? Eur Heart J 2000; 21(20): 1653-1665.
3. Gage BF et al. Validation of clinical classification schemes for predicting stroke: Results from the National Registry of Atrial Fibrillation. JAMA 2001; 285: 2864-2870.
4. Bautista LE. Inflammation, endothelial dysfunction, and the risk of high blood pressure: Epidemiologic and biological evidence. J Hum Hypertens 2003; 17: 223-230.
5. Schram MT et al. Aggressive antihypertensive therapy based on hydrochlorothiazide, candesartan or lisinopril as initial choice in hypertensive type II diabetic individuals: Effects on albumin excretion, endothelial function and inflammation in a double-blind, randomized clinical trial. J Hum Hypertens 2005; 19: 429-437.
6. Bautista LE, Vera LM, Arenas IA, Gamarra G. Independent association between inflammatory markers (C-reactive protein, interleukin-6, and TNF-alpha) and essential hypertension. J Hum Hypertens 2005; 19: 149-154.
7. Lip GYH. Hypertension and the prothrombotic state. J Hum Hypertens 2000; 14: 687-690.
8. Lip GYH. Does atrial fibrillation confer a hypercoagulable state? Lancet 1995; 346: 1313-1314.
9. Freestone B, Beevers DG, Lip GY. The renin-angiotensin-aldosterone system in atrial fibrillation: A new therapeutic target? J Hum Hypertens 2004; 18: 461-465.
10. Choudhury A, Varughese G, Lip GYH. Targeting the Renin Angiotensin Aldosterone System in Atrial Fibrillation: A shift from electrical to structural therapy? Exp Opin Pharmacother 2005 (in press).
11. Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation 1995; 92: 1954-1968.
12. Hertervig EJ et al. Evidence for electrical remodelling of the atrial myocardium in patients with atrial fibrillation. A study using the monophasic action potential recording technique. Clin Physiol Funct Imaging 2002; 22: 8-12.
13. Lau CP, Tse HF. Electrical remodelling of chronic atrial fibrillation. Clin Exp Pharmacol Physiol 1997; 24: 982-983.
14. Boldt A et al. Fibrosis in left atrial tissue of patients with atrial fibrillation with and without underlying mitral valve disease. Heart 2004; 90: 400-405.
15. Kostin S et al. Structural correlate of atrial fibrillation in human patients. Cardiovasc Res 2002; 54: 361-379.
16. Schotten U et al. Cellular mechanisms of depressed atrial contractility in patients with chronic atrial fibrillation. Circulation 2001; 103: 691-698.
17. Shi Y et al. Remodelling of atrial dimensions and emptying function in canine models of atrial fibrillation. Cardiovasc Res 2001; 52: 217-225.
18. Kaschina E, Unger T. Angiotensin AT1/AT2 receptors: Regulation, signalling and function. Blood Pressure 2003; 12: 70-88.
19. Rogg H et al. Angiotensin II-receptor subtypes in human atria and evidence for alterations in patients with cardiac dysfunction. Eur Heart J 1996; 17: 1112-1120.
20. Matsubara H. Pathophysiological role of angiotensin II type 2 receptor in cardiovascular and renal diseases. Circ Res 1998; 83: 1182-1191.
21. Goette A et al. Regulation of angiotensin II receptor subtypes during atrial fibrillation in humans. Circulation 2000; 101: 2678-2681.
22. Boldt A et al. Expression of angiotensin II receptors in human left and right atrial tissue in atrial fibrillation with and without underlying mitral valve disease. J Am Coll Cardiol 2003; 42: 1785-1792.
23. Goette A et al. Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation. J Am Coll Cardiol 2000; 35: 1669-1677.
24. Yano M et al. Differential activation of cardiac c-jun amino-terminal kinase and extracellular signal-regulated kinase in angiotensin II-mediated hypertension. Circ Res 1998; 83: 752-760.
25. Cardin S et al. Evolution of the atrial fibrillation substrate in experimental congestive heart failure: Angiotensin-dependent and -independent pathways. Cardiovasc Res 2003; 60: 315-325.
26. Engelmann MD, Svendsen JH. Inflammation in the genesis and perpetuation of atrial fibrillation. Eur Heart J [Epub ahead of print; doi:10.1093/ eurheartj/chi350].
27. Das UN. Is angiotensin-II an endogenous proinflammatory molecule? Med Sci Monit 2005; 11: RA155-RA162.
28. Tsai CT et al. Renin-angiotensin system gene polymorphisms and atrial fibrillation. Circulation 2004; 109: 1640-1646.
29. Ogimoto A et al. Relation between angiotensin-converting enzyme II genotype and atrial fibrillation in Japanese patients with hypertrophic cardiomyopathy. J Hum Genet 2002; 47: 184-189.
30. Gensini F et al. Angiotensin-converting enzyme and endothelial nitric oxide synthase polymorphisms in patients with atrial fibrillation. Pacing Clin Electrophysiol 2003; 26: 295-298.
31. Brown NJ, Vaughan DE. Prothrombotic effects of angiotensin. Adv Intern Med 2000; 45: 419-429.
32. Healey JS et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: A meta-analysis. J Am Coll Cardiol 2005; 45: 1832-1839.
33. Swedberg K et al. Prevention of atrial fibrillation in symptomatic chronic heart failure by candesartan: Results from the CHARM study (abstr). J Am Coll Cardiol 2004; 23(Suppl A): 222A.
34. Maggioni AP et al. Val-HeFT Investigators. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: Results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J 2005; 149: 548-557.
35. Wachtell K et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005; 45: 712-719.
36. Hansson L et al. Randomised trial of old and new antihypertensive drugs in elderly patients: Cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension (STOP)-2 study. Lancet 1999; 354: 1751-1756.
37. Hansson L et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611-616.
38. Vermes E et al. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: Insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials. Circulation 2003; 107: 2926-2931.
39. Pedersen OD, Bagger H, Kober L, Torp-Pedersen C. The occurrence and prognostic significance of atrial fibrillation/-flutter following acute myocardial infarction. TRACE Study group. TRAndolapril Cardiac Evalution. Eur Heart J 1999; 20: 748-754.
40. Madrid AH et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: A prospective and randomized study. Circulation 2002; 106: 331-336.
41. Ueng KC et al. Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation. Results of a prospective and controlled study. Eur Heart J 2003; 24: 2090-2098.
42. Gavras I, Gavras H. The antiarrhythmic potential of angiotensin II antagonism: Experience with losartan. Am J Hypertens 2000; 13: 512-517.
43. van Eickels M et al. Angiotensin-converting enzyme inhibitors block mitogenic signalling pathways in rat cardiac fibroblasts. Naunyn-Schmiedeberg's Arch Pharmacol 1999; 359: 394-399.
44. Li D et al. Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation 2001; 104: 2608-2614.
45. Nakashima H et al. Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation. Circulation 2000; 101: 2612-2617.
46. Kumagai K et al. Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. J Am Coll Cardiol 2003; 41: 2197-2204.
47. Kothari SA, Le MK, Gandhi PJ. Effects of angiotensin converting enzyme inhibitors on thrombotic mediators: Potential clinical implications. J Thromb Thrombolysis 2003; 15: 217-225.
48. Willaims B et al. British Hypertension Society. Guidelines for management of hypertension: Report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens 2004; 18: 139-185.
49. He FJ, MacGregor GA. Cost of poor blood pressure control in the UK: 62 000 unnecessary deaths per year. J Hum Hypertens 2003; 17: 455-457.